June Lab

Publications

  1. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev. 2015 Jan;263(1):68-89. doi:10.1111/imr.12243. PubMed PMID: 25510272.
  2. Duda GN, Grainger DW, Frisk ML, Bruckner-Tuderman L, Carr A, Dirnagl U, Einhäupl KM, Gottschalk S, Gruskin E, Huber C, June CH, Mooney DJ, Rietschel ET, Schütte G, Seeger W, Stevens MM, Urban R, Veldman A, Wess G, Volk HD. Changing the mindset in life sciences toward translation: a consensus. Sci Transl Med. 2014 Nov 26;6(264):264cm12. doi: 10.1126/scitranslmed.aaa0599. PubMed PMID:25429054.
  3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. PubMed PMID: 25317870; PubMed Central PMCID:PMC4267531.
  4. June CH. Toward synthetic biology with engineered T cells: a long journey just begun. Hum Gene Ther. 2014 Sep;25(9):779-84. doi: 10.1089/hum.2014.2533. PubMed PMID: 25244569; PubMed Central PMCID: PMC4174426.
  5. Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, Zhang PJ, Tchou J. Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat. 2014 Oct;147(3):675-84. doi:10.1007/s10549-014-3077-5. Epub 2014 Sep 6. PubMed PMID: 25193277; PubMed Central PMCID: PMC4261925.
  6. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, Barrett DM, Zhao Y. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7. PubMed PMID: 25104548.
  7. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 2014 Jul 1. pii: blood-2013-10-535245. [Epub ahead of print] PubMed PMID: 24986688.
  8. June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014 Jun 19. [Epub ahead of print] PubMed PMID: 24943274.
  9. Maus M, June CH. CARTs on the road for myeloma. Clin Cancer Res. 2014 Jun 11. pii: clincanres.0721.2014. [Epub ahead of print] PubMed PMID: 24919574
  10. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, June CH, Riley J, Wherry EJ, Albelda SM. Multifactorial T cell Hypofunction That is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors. Clin Cancer Res. 2014 Jun 11. pii: clincanres.2627.2013. [Epub ahead of print] PubMed PMID: 24919573.
  11. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014 Feb;2(2):154-66. doi: 10.1158/2326-6066.CIR-13-0027. Epub 2013 Nov 12. PubMed PMID: 24778279; PubMed Central PMCID: PMC4007316
  12. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7. PubMed PMID: 24777247.
  13. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014 Mar 6;370(10):901-10. doi: 10.1056/NEJMoa1300662. PubMed PMID: 24597865; PubMed Central PMCID: PMC4084652.
  14. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. PubMed PMID: 24596416; PubMed Central PMCID: PMC3983612